1
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Endothelin and acute renal dysfunction after coronary artery bypass grafting

, &
Pages 153-160 | Published online: 04 Dec 2011

References

  • Brivet FG, Kleinknecht DJ, Loirat P, Landais PJM, The French Study Group on Acute Renal Failure. Acute renal failure in intensive care units - Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. Grit Care Med 1996; 24: 192–8.
  • Turney JH, Marshall DH, Brownjohn AM, Ellis CM, Parsons FM. The evolution of acute renal failure, 1956–1988. QJM 1990 74: 83–104.
  • Cameron JS. Acute renal failure - the continuing challenge. QJM 1986; 59: 337–43.
  • Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994; 78: 143–9.
  • Yeboah ED, Petrie A, Pead JL. Acute renal failure and open heart surgery. BMJ 1972; i: 415–8.
  • Abel RM, Buckley MJ, Austen WG, Barnett GO, Beck Jr CH, Fischer JE. Etiology, incidence, and prognosis of renal failure following cardiac operations. Results of a prospective analysis of 500 consecutive patients. J Thorac Cardiovasc Surg 1976; 71: 323–33.
  • Hilberman M, Myers BD, Carrie BJ, Derby G, Jamison RL, Stinson EB. Acute renal failure following cardiac surgery. J Thorac Cardiovasc Surg 1979; 77: 880–8.
  • Kron IL, Joob AW, Van Meter C. Acute renal failure in the cardiovascular surgical patient. Ann Thorac Surg 1985; 39: 590–8.
  • Koning HM, Koning AJ, Leusink JA. Serious acute renal failure following open heart surgery. Thorac Cardiovasc Surg 1985; 33: 283–7.
  • Lange HW, Aeppli DM, Brown DC. Survival of patients with acute renal failure requiring dialysis after open heart surgery: Early prognostic indicators. Am Heart J 1987; 113: 1138–43.
  • Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg 1989; 98: 1107–12.
  • Schmitt H, Riehl J, Bosiela A et al. Acute renal failure followingcardiac surgery: pre- and postoperative clinical features. Contrib Nephrol 1991; 93: 98–104.
  • Zanardo G, Michielon P, Paccagnella A et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg 1994; 107: 1489–95.
  • Llopart T, Lombardi R, Forselledo M, Andrade R. Acute renal failure in open heart surgery. Ren Fail 1997; 19: 319–23.
  • Rasmussen HH, Ibels LS. Acute renal failure. Multivariate analysis of causes and risk factors. Am J Med 1982; 73: 211–8.
  • Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243–8.
  • Wilkes BM, Mailloux LU. Acute renal failure. Pathogenesis and prevention. Am J Med 1986; 80: 1129–36.
  • Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med 1987; 83: 65–71.
  • Groeneveld ABJ, Tran DD, Meulen J van der, NautaJJP, Thijs LG. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron 1991; 59: 602–10.
  • Kellen M, Aronson S, Roizen MF, Barnard J, Thisted RA. Predictive and diagnostic tests of renal failure. Anesth Analg 1994; 78: 134–42.
  • Mazzarella V, Taccone Gallucci M, Tozzo C et al. Renal function in patients undergoing cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1625–7.
  • Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314: 97–105.
  • Thadani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448–60.
  • Koning HM, Leusink JA, Nas AA et al. Renal function following open heart surgery: The influence of postoperative artificial ventilation. Thorac Cardiovasc Surg 1987; 36: 1–5.
  • Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 1995; 332: 647–55.
  • Urzua J, Troncoso S, Bugedo G et al. Renal function and cardiopulmonary bypass: Effect of perfusion pressure. J Cardiothorac Vasc Anesth 1992; 6: 299–303.
  • Slogoff S, Reul GJ, Keats AS et al. Role of perfusion pressure and flow in major organ dysfunction after cardiopulmonary bypass. Ann Thorac Surg 1990; 50: 911–8.
  • Ip-Yarn PC, Murphy S, Baines M, Fox MA. Desmond MJ, Innes PA. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 1994; 78: 842–7.
  • Knudsen F, Andersen LW. Immunological aspects of cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1990; 4: 245–58.
  • Henderson LW, Chenoweth D. Biocompatibility of artificial organs: an overview. Blood Purif 1987; 5: 100–11.
  • Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987; 316: 1525–30.
  • Moat NE, Shore DF, Evans TW. Organ dysfunction and cardiopulmonary bypass: the role of complement and complement regulatory proteins. Eur J Cardiothorac Surg 1993; 7: 563–73.
  • Jacob SH, Craddock PR, Hammerschmidt DE, Moldow CF. Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. N Engl J Med 1980; 302: 789–94.
  • Rocke DA, Gaffin SL, Wells MT et al. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93: 832–7.
  • Kharazmi A, Andersen LW, Baek L et al. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98: 381–5.
  • Casey WF, Hauser GJ, Hannallah RS et al. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit Care Med 1992; 20: 1090–6.
  • Andersen LW, Landow L, Beak L et al. Association between gastric intramucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor concentrations in patients undergoing cardiopulmonary bypass. Grit Care Med 1993; 21: 210–7.
  • Groeneveld ABJ. Pathogenesis of acute renal failure during sepsis. Nephrol Dial Transplant 1994; 9(Suppl 4): 47–51.
  • Chertow GM, Lazarus M, Christiansen CL et al. Preoperative renal risk stratification. Circulation 1997; 95: 878–84.
  • Pascual J, Liano F, Ortuno J. The elderly patient with acute renal failure. J Am Soc Nephrol 1995; 6: 144–53.
  • Shankel SW, Johnson DC, Clark PS, Shankel TL, O'Neil Jr WM. Acute renal failure and glomerulopathy caused by nonsteroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 986–90.
  • Miller TR, Anderson RJ, Linas SL et al. Urinary diagnostic indices in acute renal failure. A prospective study. Ann Intern Med 1978; 89: 47–50.
  • Bonventre JV. Mechanisms of ischemic acute renal failure. Kidney Int 1993; 43: 1160–78.
  • McCord JM. Oxygen derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159–163.
  • Editorial. Adenosine revisited. Lancet 1985; i: 7–8.
  • Bidani A, Churchill P. Hemodynamically-mediated acute renal failure. N Engl J Med 1986; 314: 1545–6.
  • Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5.
  • Yanagisawa M, Masaki T. Endothelin, a novel endothelium-derived peptide. Biochem Pharmacol 1989; 38: 1877–83.
  • Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 375–411.
  • Levin ER. Endothelins. N Engl J Med 1995; 333: 356–63.
  • Remuzzi G, Benigni A. Endothelins in the control of cardio-vascular and renal function. Lancet 1993; 342: 589–93.
  • Turner AJ, Murphy U. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 1996; 51: 91–102.
  • Clavell AL, Stingo AJ, Margulies KB, Brandt RR, Burnett JC Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol 1995; 268: F455–60.
  • Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431–8.
  • Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 1989; 83: 317–20.
  • King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256: F1051–8.
  • Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology. Kidney Int 1994; 46: 376–81.
  • Clavell AL, Burnett JC Jr. Physiologic and pathophysiologic roles of endothelin in the kidney. Curr Opin Nephrol Hypertens 1994; 3: 66–72.
  • Simonson MS, Dunn MJ. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med 1992; 119: 622–39.
  • Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852–4.
  • Vanhoutte PM. Other endothelium-derived vasoactive factors. Circulation 1993; 87[suppl V]: V9–17.
  • Vane JR, iknggard EE, Bolting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27–36.
  • Vanhoutte PM, Liischer TF, Gräser T. Endothelium-dependent contractions. Blood Vessels 1991; 28: 74–83.
  • Lopez JA, Armstrong ML, Piegors DJ, Heistad DD. Vascular responses to endothelin-1 in atherosclerotic primates. Arteriosclerosis 1990; 10: 1113–18.
  • Wilkins FC Jr, Alberola A, Mizelle HL, Opgenorth TJ, Granger JP. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol 1995; 268: R375–81.
  • Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573–9.
  • Lerman A, Edwards BS, Hallet JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997–1001.
  • Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1992; 77: 96–100.
  • Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464–9.
  • Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1991; 328: 1732–9.
  • Ohta K, Hirata Y, Shichiri M et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 9: 307–11.
  • Brooks DP, Ohlstein EH, Contino LC et al. Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. Eur J Pharmacol 1991; 194: 115–7.
  • Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989; i: 991–2.
  • Mallamaci F, Parlongo S, Zoccali C. Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 1993; 63: 291–5.
  • Pei Y, Chan C, Cattran D et al. Sustained vasoconstriction associated with daily cyclosporine dose in heart and lung transplant recipients: potential pathophysiologic role of endothelin. J Lab Clin Med 1995; 125: 113–9.
  • Bird JE, Giancarli MR, Megill JR, Durham SK. Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol 1996; 7: 1153–7.
  • Moore K, Wendon J, Frazer M, Karani J, Williams R, Bath K. Plasma endothelin immunoreactivity in liver disease and hepatorenal syndrome. N Engl J Med 1992; 327: 1774–8.
  • Epstein M, Goligorsky MS. Endothelin and nitric oxide in hepato-renal syndrome: a balance reset. J Nephrol 1997; 10: 120–35.
  • Firth JD, Ratcliffe PJ, Raine AE, Ledingham JGG. Endothelin: an important factor in acute renal failure? Lancet 1988; 1179–82.
  • Tomita K, Ujiie K, Nakanishi T et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 321: 1127 (Letter).
  • Peco-Antic A, Nastic-Miric D, Popovic Rolovic M, Adanj a G, Kostic M, Paripovic V. Endothelin-1 in acute renal failure. Ren Fail 1996; 18: 553–6.
  • Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996; 49: 181–9.
  • Hunley TE, Kon V. Endothelin in ischemic acute renal failure. Curr Opin Nephrol Hypertens 1997; 6: 394–400.
  • Kohan DE. Role of endothelin and tumour necrosis factor in the renal response to sepsis. Nephrol Dial Transplant 1994; 9\(suppl 4): 73–7.
  • Badr KF. Sepsis-associated renal vasoconstriction: potential targets for future therapy. Kidney Int 1992; 20: 207–13.
  • Burke TJ, Arnold PE, Gordon JA, Bulger RE, Dobyan DC, Schrier RW. Protective effect of intrarenal calcium membrane blockers before and after renal ischemia. Functional, morpho-logical, and mitochondrial studies. J Clin Invest 1984; 74: 1830–41.
  • Loutzenhiser R, Epstein M, Horton C. Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney. Am J Cardiol 1987; 59: 72A–75A.
  • Loutzenhiser R, Epstein M. Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists. Am J Nephrol 1987; 7(Suppl 1): 7–16.
  • Cao L, Banks RO. Cardiovascular and renal actions of endothelin: effects of calcium-channel blockers. Am J Physiol 1990; 258: F254–8.
  • Shibouta Y, Suzuki N, Shino A et al. Pathophysiological role of endothelin in acute renal failure. Life Sci 1990; 46: 161–8.
  • Kiowski W, Liischer TF, Linder L, Biihler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium-channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83: 469–75.
  • Garcia Cosmes P, Mortezo A, Lopez Novoa JM, Macias Nunez JF. Is renal protection with calcium antagonists possible?Drugs 1992; 44(Suppl 1): 99–102.
  • Chan L, Chittinadana A, Shapiro JI, Shanley PF, Schrier RW. Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am J Physiol 1994; 266: F135–8.
  • Gellai M, Jugus M, Fletcher T, DeWolf R, Nambi P. Reversal of postischemic acute renal failure with a selective endothelin A. Receptor antagonist in the rat. J Clin Invest 1994; 93: 900–6.
  • Kivlighn SD, Gabel RA, Siegl PK. Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction. Kidney Int 1994; 45: 131–6.
  • Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990; 1: 76–83.
  • Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 1992; 42: 770–4.
  • Benigni A, Zola C, Coma D et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440–4.
  • Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Biological role for the endothelin-A receptor in aortic cross-clamping. Hypertension 1993; 22: 62–6.
  • Kato T, Kassab S, Wilkins FC Jr, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 1995; 25: 883–7.
  • Clozel M, Breu V, Burn i K et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759–61.
  • Benigni A, Zoja C, Coma D et al. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996; 27: 416–23.
  • Oldroyd SD, Haylor IL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 1995; 196: 661–5.
  • Vemalapulli S, Chiu PJ, Chintala M, Bernardino V. Attenuation of ischemic acute renal failure by phosphomaridon in rats. Pharmacology 1993; 47: 188–93.
  • Matheis G, Haak T, Beyersdorf F, Baretti R, Polywka C, Winkelmann BR. Circulating endothelin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 1995; 9: 269–74.
  • Hahnel J, Mutscheler D, Huhn W et al. Perioperative Endothelin-, ACTH- und Kortisolplasmakonzentrazionen bei Koronarbypasspatienten. Anaesthesist 1994; 43: 635–41.
  • Onizuka M, Miyauchi T, Mitsui K et al. Plasma levels of endothelin-1 and thrombin-antithrombin III complex in patients undergoing open chest operations. J Thorac Cardiovasc Surg 1993; 105: 559–60.
  • Pasaoglu I, Erbas B, Varoglu E et al. Changes in the circulating endothelin and atrial natriuretic peptide levels during coronary artery bypass surgery. Jpn Heart J 1993; 34: 693–706.
  • Komai H, Adatia IT, Elliott MJ, Leval MR de, Haworth SG. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993; 106: 473–8.
  • Zhu ZG, Wang MS, Jiang ZB et al. The dynamic change of plasma endothelin-1 during the perioperative period in patients with rheumatic valvular disease and secondary pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108: 960–8.
  • Conger JD. Interventions in acute renal failure: What are the data? Am J Kidney Dis 1995; 26: 565–76.
  • Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322: 825–9.
  • Myles PS, Buckland MR, Schenk NJ et al. Effect of 'renal-dose' dopamine on renal function following cardiac surgery. Anaesth Intensive Care 1993; 21: 56–61.
  • Baldwin L, Handerson A, Hickman P. Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery. Ann Intern Med 1994; 120: 744–7.
  • Thompson BT, Cochin BA. Renal-dose dopamine: a siren song? Lancet 1994; 344: 7–8.
  • Hynynen M, Palojoki R, Heinonen J, Tikkanen I, Harjula All, Fyhrquist F. Renal and vascular effects of atrial natriuretic factor during cardiopulmonary bypass. Chest 1991; 100: 1203–9.
  • Meyer M, aerbacher HJ, Bohm E, Seib:4)e KB, Brett W, Forssmann WG. Ularitide: from renal natriuretic peptide to clinical trials. Curr Opin Nephrol Hypertens 1996; 5: 366–70.
  • Valenberg PLJ van, Hoitsma AJ, Tiggeler RGWL. Mannitol as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. Transplantation 1987; 44: 784–8.
  • Beutler B, Krochin N, Milsark IW et al. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 1986; 232: 977–80.
  • Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 1987; 45: 348–55.
  • Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991; 121: 20–4.
  • Tsang GMK, Khan I, Dar M, Clayton D, Waller D, Patel RL. Hemofiltration in a cardiac intensive care unit: time for a rational approach. ASAIO J1996; 42: M710–3.
  • Nair P, Bihari D. Acute renal failure in the ICU in the 1990s - 'anything goes'? Intensive Care Med 1997; 23: 1193–6.
  • Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20: 724–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.